




Biomarkers useful across the clinical continuum






Use of blood based biomarkers in all care settings



Biomarker panel

- AB42/AB40
- pTau-181
 - NfL
- GFAP



Impact:

- Accessible, objective, timely diagnosis
- Increased access by ethnic minority groups
- No overload of second- and third-line care



Adoption of blood test in primary care practice?

Opportunities

Cost-effective

Broad coverage

Non-invasive

Life decision management for patients

Better communication with family



Challenges

Accessibility and sample handling

Need for infrastructure

Lack of training and time

Lack of clear guidelines


Lack of standardisation

Result interpretation


Low awareness among PCPs

Potential increase in referrals and further testing

5 subtypes within the AD population






Tijms et al, Nat Aging 2024





Roadmap for development of biomarkers






Biomarker Panel Development using novel technologies

AD vs. CON


AD vs. CON
(8-CSF AD-diagnostic panel)



Discovery

AD, Alzheimer's disease; AUC, area under the curve; CON, control; CSF, cerebrospinal fluid.
Del Campo et al. Nat Aging In press.

AD vs. CON
(AD-diagnostic panel)



Custom panels